文献速递泌尿生殖腹部MR

低剂量钆对比剂动态对比增强磁共振成像在前列腺癌诊断中的可行性:与标准剂量的性能比较

Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis.
PubMed 文献 · Invest Radiol · 2018-01-01

本研究纳入17例组织学确诊前列腺癌患者,在3 T MRI下分别注射低剂量(0.015 mmol/kg)和接近标准剂量(0.085 mmol/kg)钆布醇进行动态对比增强MRI,比较两者区分前列腺癌与良性组织的能力。结果显示两种剂量定性评估敏感度相似(均为13/26=50%),但低剂量信号增强率α区分癌与良性组织的AUC(0.769)高于标准剂量(0.625)。作者认为基于信号增强率,低剂量动态对比增强MRI区分前列腺癌与良性组织似乎比标准剂量更有效,定性评估诊断准确性相似。

要点

  • 低剂量与标准剂量动态对比增强MRI定性诊断前列腺癌敏感度均为13/26=50%。
  • 低剂量信号增强率α区分前列腺癌与良性组织AUC为0.769,高于标准剂量的0.625。
  • 低剂量与标准剂量最大增强投影MEP诊断前列腺癌与正常组织间无显著差异。

核心结论

  • 初步结果提示,基于信号增强率,低剂量钆对比剂动态对比增强MRI区分前列腺癌与良性前列腺组织似乎比标准剂量更有效,定性评估诊断准确性相似;低剂量钆对比剂动态对比增强MRI诊断前列腺癌可能可行,且低剂量与高剂量对比剂后增强动力学比较可能提供有诊断价值的信息。

研究设计与样本

  • 前瞻性可行性研究,纳入17例组织学确诊前列腺癌患者,术前行3 T MRI,采用8.3秒时间分辨率,分别以低剂量(0.015 mmol/kg)和接近标准剂量(0.085 mmol/kg)钆布醇团注采集动态对比增强MRI,低剂量采集3.5分钟后间隔5分钟再采集标准剂量8.3分钟。

诊断标准与关键数值

  • 定性分析显示低剂量与标准剂量动态对比增强MRI诊断前列腺癌敏感度均为13/26=50%,病灶可见度评分低剂量4.0±1.0 vs 标准剂量4.2±0.9(P=0.317);定量分析显示前列腺癌信号增强率α在低剂量下为9.98±5.84 s、良性组织为5.12±2.95 s,差异显著,标准剂量下前列腺癌为4.27±2.20 s、良性组织为3.35±1.48 s,差异不显著;低剂量α与标准剂量α比值前列腺癌为2.8±2.3、正常前列腺为1.6±0.9(P=0.02);α区分前列腺癌与良性组织的受试者工作特征曲线下面积低剂量为0.769、标准剂量为0.625;最大增强投影MEP在低剂量与标准剂量下前列腺癌与正常组织间均无显著差异;低剂量与标准剂量间MEP(r=0.53)和α(r=0.58)呈中度显著Pearson相关。

临床应用与阅片要点

  • 作者认为低剂量钆对比剂动态对比增强MRI诊断前列腺癌可能可行,低剂量与高剂量对比剂后增强动力学比较可能提供有诊断价值的信息。

局限性

  • 原文结论称这些为初步结果。
  • 原文结论称前列腺癌诊断用低剂量钆对比剂动态对比增强MRI可能可行(may be feasible)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study investigates whether administration of low doses of gadolinium-based contrast agent (GBCA) for dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) can be as effective as a standard dose in distinguishing prostate cancer (PCa) from benign tissue. In addition, we evaluated the combination of kinetic parameters from the low- and high-dose injection as a new diagnostic marker.

MATERIALS AND METHODS: Patients (n = 17) with histologically confirmed PCa underwent preoperative 3 T MRI. Dynamic contrast-enhanced MRI images were acquired at 8.3-second temporal resolution with a low dose (0.015 mmol/kg) and close to the standard dose (0.085 mmol/kg) of gadobentate dimeglumine bolus injections. Low-dose images were acquired for 3.5 minutes, followed by a 5-minute gap before acquiring standard dose images for 8.3 minutes. The data were analyzed qualitatively to investigate whether lesions could be detected based on early focal enhancement and quantitatively by fitting signal intensity as a function of time with an empirical mathematical model to obtain a maximum enhancement projection (MEP) and signal enhancement rate (α).

RESULTS: Both low- and standard-dose DCE-MRI showed similar sensitivity (13/26 = 50%) and lesion conspicuity score (4.0 ± 1.0 vs 4.2 ± 0.9; P = 0.317) for PCa diagnosis on qualitative analysis. Prostate cancer showed significantly increased α compared with benign tissue for low (9.98 ± 5.84 vs 5.12 ± 2.95 s) but not for standard (4.27 ± 2.20 vs 3.35 ± 1.48 s) dose. The ratio of low-dose α to standard-dose α was significantly greater (P = 0.02) for PCa (2.8 ± 2.3) than for normal prostate (1.6 ± 0.9), suggesting changes in water exchange and T2* effects associated with cancer. In addition, decreases in the percentage change in T1 relaxation rate as a function of increasing contrast media concentration (ie, the "saturation effect") can also contribute to the observed differences in high-dose and low-dose α. Area under the receiver operating characteristic curve for differentiating PCa from benign tissue using α was higher for low dose (0.769) compared with standard dose (0.625). There were no significant differences between MEP calculated for PCa and normal tissue at the low and standard doses. Moderate significant Pearson correlation for DCE parameters, MEP (r = 0.53) and α (r = 0.58), was found between low and standard doses of GBCA.

CONCLUSIONS: These preliminary results suggest that DCE-MRI with a low GBCA dose distinguishes PCa from benign prostate tissue more effectively than does the standard GBCA dose, based on signal enhancement rate. Diagnostic accuracy is similar on qualitative assessment. Prostate cancer diagnosis may be feasible with DCE-MRI with low-dose GBCA. In addition, comparison of enhancement kinetics after low and high doses of contrast media may provide diagnostically useful information.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. He D, Chatterjee A, Fan X, et al. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018. PMID: 29702525. doi:10.1097/RLI.0000000000000466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。